Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Feb 14, 2021 1:42pm
142 Views
Post# 32565047

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq
3burtc wrote: Doesn't matter mugs, amalgamation doesn't happen unless company is on the move! Clearly they are still working on it. No way Dan takes I.P. out of protection unless the company is being sold! That's why your argument for dilution is bogus! Big pharma is smart and would rather own instead of rent. Anyone who sits back and does nothing to acquire ate will pay for generations to come!


Don't think I argued for dilution.
But ... dilution is still on the table.
Will be on the table until they have enough cash ... whatever they deam that to be.
Likely coser to $150M in the bank - but that depends on their strategy.
Acquisition is possible but I wouldn't bet cash on it.

Like I said ... I'll take it whatever way it comes.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities